SCHEMBL24847741

SCHEMBL24847741

COc1nc(O)ccc1C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.39
CA1 P00915 2/20 0.39
ALOX15 P16050 3/20 0.37
LMNA P02545 2/20 0.37
TP53 P04637 1/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37
PTGS2 P35354 2/20 0.35
ALDH1A1 P00352 6/20 0.34
TDP1 Q9NUW8 2/20 0.34
TSHR P16473 1/20 0.34
CYP1A2 P05177 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
PTGS1 P23219 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
ATP2A2 P16615 1/20 0.33
ATP2A3 Q93084 1/20 0.33
SQOR Q9Y6N5 1/20 0.33
TYR P14679 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9906400 0.78 POLB (0.47) CA2CA1HPGDALDH1A1TDP1
SCHEMBL12139712 0.78 APOBEC3A (0.38) CA2CA1LMNATP53HPGD
SCHEMBL18538044 0.78 SQOR (0.39) CA2CA1ALOX15LMNATP53
SCHEMBL13920277 0.74 CA2 (0.41) CA2CA1ALOX15LMNAALDH1A1
SCHEMBL23588457 0.73 HSD17B10 (0.38) PTGS2ALDH1A1PTGS1KDM4EMAPT
SCHEMBL22688378 0.73 NNMT (0.46) CA2CA1TP53HPGDALDH1A1
SCHEMBL12062496 0.72 POLB (0.34) HPGDALDH1A1TDP1CYP1A2KDM4E
SCHEMBL12435246 0.72 CA2 (0.39) CA2CA1ALOX15LMNATP53
SCHEMBL23483643 0.72 ALOX5AP (0.33) SQOR
SCHEMBL22096312 0.72 CCR1 (0.39) ALDH1A1MAPTSQOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002361-A1 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002361-A1 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE IRAK4, IRAK3, IRAK2 CA2 2445/4885CA1 4725/4885ALOX15 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.